2 European Courts Reject Fosamax Patents
In a double whammy for a Merck & Co. subsidiary, two European courts have separately knocked down the drug manufacturer's key patent covering a generic version of its osteoporosis drug Fosamax,...To view the full article, register now.
Already a subscriber? Click here to view full article